VTR
47
-7
WFC
79
4
DFS
64
2
ORLY
62
2
NEE
50
-5
FE
50
-2
JPM
69
2
DD
63
3
EQT
57
-2
MCD
52
2
PSA
58
2
CRM
67
2
MLM
57
6
GE
67
2
MAT
46
12
WEC
53
-2
TSCO
49
5
UPS
60
9
AAP
24
6
INTU
56
-4
VTR
47
-7
WFC
79
4
DFS
64
2
ORLY
62
2
NEE
50
-5
FE
50
-2
JPM
69
2
DD
63
3
EQT
57
-2
MCD
52
2
PSA
58
2
CRM
67
2
MLM
57
6
GE
67
2
MAT
46
12
WEC
53
-2
TSCO
49
5
UPS
60
9
AAP
24
6
INTU
56
-4
Financhill
Back

Sinovac Biotech 10K Form

Sell
38

SVA
Sinovac Biotech

Last Price:
6.47
Seasonality Move:
4.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SVA News And Ratings

See the #1 stock for the next 7 days that we like better than SVA

SVA Financial Statistics

Sales & Book Value

Annual Sales: $448.27M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $120.36
Price / Book: 0.05

Profitability

EPS (TTM): -1.31000
Net Income (TTM): $-124.73M
Gross Margin: $266.75M
Return on Equity: -1.05%
Return on Assets: -0.93%

Sinovac Biotech Earnings Forecast

Key Sinovac Biotech Financial Ratios

  • The Gross Profit Margin over the past 24 years for SVA is 59.51%.
  • The Selling, General & Administrative Expenses for SVA have been equal to 104.03% of Gross Profit Margin.
  • The Research & Development expenses have been 76.85% of Revenue.
  • The Interest Expense is -2.26% of Operating Income.
  • The Net Earning history of SVA is -22.29% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 11 years.

Sinovac Biotech Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SVA
CUSIP: P8696W
Website: sinovac.com

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 11.39
Quick Ratio: 11.22

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SVA Technical Analysis vs Fundamental Analysis

Sell
38
Sinovac Biotech (SVA) is a Sell

Is Sinovac Biotech a Buy or a Sell?

  • Sinovac Biotech stock is rated a Sell
    The current Sinovac Biotech [SVA] share price is $6.47. The Score for SVA is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.